Synergistic PIM Kinase and Proteasome Inhibition as a Therapeutic Strategy for MYC-Overexpressing Triple-Negative Breast Cancer

The PIM family of kinases has emerged as a factor that is both overexpressed in TNBC and associated with poor outcomes. The authors’ screening effort identified PIM and the 20S proteasome inhibition as the most synergistic combination.